How it is happening now: the patient has been diagnosed with COVID-19.
- How do you feel?
- More or less normal...
- Well, then, go home, if it gets worse - call...
Medical product Antipathogenic agent "Sanation + Anticovid" was developed and registered by Israeli and Ukrainian scientists as a means of emergency treatment of the early stage of COVID-19.
Medical product Antipathogenic agent "Sanation + Anticovid" allows, by inhalation, to neutralize/kill 98% - 99% of the COVID infection, normalizes the patient's condition and prevents the transition of the disease from a mild or moderate course of the disease to a more severe or critical form.
The drug was practically used in the treatment of 93 patients with a diagnosis of COVID-19 of varying severity in 4 medical institutions, namely:
1. Military Medical Clinical Center of the Western Region of the Ministry of Defense of Ukraine
2. Communal non-commercial enterprise "Clinical hospital of urgent medical care of the city of Lviv"
3. Communal non-commercial enterprise "Odesa Regional Clinical Medical Center" of the Odesa Regional Council"
4. Municipal non-commercial enterprise "City Clinical Hospital No. 11" of the Odesa City Council.
During the first 24 hours of use of the "Antipathogenic agent" Sanation + Anticovid" patients observed the disappearance of symptoms of COVID-19, there were no sudden changes in conditions, the effect of a cytokine storm, sudden changes in body temperature and blood saturation indicators. There were no facts of the transition of the average severity of the course of the disease to severe or critical form. There were no facts of the development of lung inflammation (pneumonia) and other complications.
The recovery period of patients with a diagnosis of COVID-19, in the treatment of which the Antipathogenic agent "Sanation + Anticovid" was used, was reduced by 2-3 times, from 27-30 days to 7-10 days. The medical product "ANTIPATHOGENIC AGENT "SANATSIA+ANTIKOVID" is intended for use with portable or stationary nebulizers (inhalers) during inhalation, as well as ventilators and oxygen concentrators - as a liquid for moistening the oxygen-air mixture.
Due to high physicochemical activity to pathogens, including Sars-COV-2 of all strains, the use of the medical device is highly effective in the treatment of COVID-19. DESCRIPTION OF THE MEDICAL PRODUCT
The medical product "ANTIPATHOGENIC AGENT "SANATSIA+ ANTICOVID" is a transparent, homogeneous, colorless liquid with a light specific smell of chlorine without mechanical impurities, is a metastable mixture of peroxide and oxygen chloride compounds, which are formed by the action of electrochemical activation of a salt solution (NaCl) in drinking water, containing: water (H2O) 99.690%, sodium chloride (NaCL) 0.260%, hypochlorous acid (HOCL) 0.045%, hypochlorite ion 0.005%.
The mass concentration of active chlorine is 0.035%. SAFETY
Hydrochloric acid (HOCl) and hypochlorite ion are produced by the human body as the main protective component of the immune system in the fight against pathogens (bacteria, viruses, fungi), due to which the drug is non-toxic, safe to use and is perceived by the human body as its own substance. The US Environmental Protection Agency classifies perchloric acid (HOCl) at neutral pH as a safe element that does not cause corrosion or irritation.
Application of the medical product "ANTIPATHOGENIC AGENT "SANATSIA+ANTIKOVID"
to provide treatment and facilitate the course of the disease by physicochemical action on coronaviruses of all strains on the mucous membranes of the respiratory tract, according to Protocol No. 3/28-А-2394-21 of preclinical tests dated 09.09.2021 SE "Scientific Center of Preventive Toxicology, Food and chemical safety named after Academician L.I. Bear of the Ministry of Health of Ukraine" is safe. ANTIPATHOGENIC ACTIVITY
Hydrochloric acid and hypochlorite ion have high activity against viruses, microbes, fungi, which is confirmed by both in vitro and in vivo studies. The mechanism of action of the physico-chemical action of the medical product ANTI-PATHOGENIC AGENT "SANATSIA+ ANTICOVID" consists in washing away and oxidizing pathogens on mucous membranes - atomic chlorine reduces the activity of amino groups of proteins, preventing the formation of polypeptide chains, while oxygen and hypochlorite ion oxidize and coagulate the proteins of disease-causing agents, which leads to their death. The effectiveness of the medical product is similar to that of an antibiotic, but without harming the human body and without causing addiction and other negative side effects.
Scientific research of the State University "Institute of Public Health named after OHM. Marzeev National Medical University" the high activity of the
ANTIPATHOGENIC MEDICINE "SANATSIA+ ANTICOVID" against RNA- and DNA-containing viruses, including against SARS-CoV-2 coronaviruses of all strains, polioviruses, poliomyelitis, hepatitis A, hepatitis B, rotaviruses, adenoviruses, influenza , herpes virus (HSV); gram-positive and gram-negative, aerobic and anaerobic bacteria, including bacteria of the Enterobacteriacae family, pathogens of Pseudomonas aeruginosa, Enterococcus family, Staphylococcus aureus, the causative agent of tuberculosis Mycobacterium tuberculosis, in the form of monocultures and microbial associations, including hospital strains resistant to antibiotics; fungi of the genus Candida, Aspergillus brasiliensis, dermatophytes in the form of monocultures and microbial associations, including fungal microflora with resistance to chemotherapeutic drugs. EFFICIENCY during treatment:
Scientific studies have established that the epithelium of the nasal cavity is the main portal of entry for respiratory viruses and a direct target for viral replication in the respiratory tract. It serves as a mechanical barrier to protect against environmental factors, microorganisms and toxins, and also participates in both innate and adaptive immune responses.
From the moment coronaviruses hit the mucous membrane to the moment they enter the human body, a certain amount of time passes, which is necessary for the dissolution of the virus envelope.
Carrying out inhalations using a medical product and/or its use in ventilators and oxygen concentrators as a liquid to moisten the oxygen-air mixture, especially in the initial stages of the disease of COVID-19, leads to a significant reduction of pathogens, including Sars-COV-2 of all strains on the mucous membranes of the respiratory organs, which makes it possible to achieve the following indicators:
- absence of sudden changes in states, indicators of body temperature and blood saturation;
- absence of facts of the transition of the average severity of the course of the disease into severe and critical forms;
- no development of lung inflammation (pneumonia) and other complications;
- reduction of the total period (time) of treatment by 2-3 times. USE THE MEDICAL PRODUCT IN THE PROCEDURE DETERMINED BY THE INSTRUCTIONS